RARE
NASDAQ
US
Ultragenyx Pharmaceutical Inc. - Common Stock
$22,45
▲ +$1,03
(+4,81%)
Vol 1.8M
5
Skor Kualitas
fail
Pendapatan ✗
Laba Bersih ✗
>IPO ✗
Kap. Pasar
$2.2B
ROE
-414,2%
Margin
-92,0%
D/E
8352,12
Beta
0,10
52W
$26–$47
Konsensus Wall Street
26 analis · Apr 20268
Beli Kuat
15
Beli
3
Tahan
0
Jual
0
Jual Kuat
88,5%
Peringkat Beli
Grafik Harga
Saham Serupa
MLYS
Mineralys Therapeutics Inc
$2.9B
SNDX
Syndax Pharmaceuticals Inc
$1.8B
DAWN
Day One Biopharmaceuticals Inc
$956.9M
ADMA
ADMA Biologics Inc
P/E 20,7
$4.3B
TYRA
Tyra Biosciences Inc
$1.4B
CLDX
Celldex Therapeutics Inc
$1.8B
AGIO
Agios Pharmaceuticals Inc
$1.6B
SLNO
Soleno Therapeutics Inc
$2.5B
STOK
Stoke Therapeutics Inc
P/E 44,2
$1.8B
VRDN
Viridian Therapeutics Inc
$3.0B
Pendapatan
Tingkat beat: 50,0%| Kuartal | EPS Estimasi | EPS Aktual | Kejutan |
|---|---|---|---|
| Des 2025 | $-1,11 | $-1,29 | $-0,18 |
| Sep 2025 | $-1,26 | $-1,81 | $-0,55 |
| Jun 2025 | $-1,32 | $-1,17 | +$0,15 |
| Mar 2025 | $-1,65 | $-1,57 | +$0,08 |
Tren Fundamental
| Metrik | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -237.5% | -237.5% | -237.5% | -237.5% | -414.2% | -414.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -69.0% | -87.3% | -87.3% | -87.3% | -92.0% | -92.0% |
| Gross Margin | 86.2% | 85.3% | 85.3% | 85.3% | 84.7% | 84.7% |
| D/E Ratio | 559.61 | 0.00 | 559.61 | 559.61 | 8352.12 | 8352.12 |
| Current Ratio | 2.45 | 2.45 | 2.45 | 2.45 | 1.89 | 1.89 |
Rasio Utama
ROA (TTM)
-43,7%
P/S (TTM)
3,52
P/B
15,2
EPS (TTM)
$-5,94
CF/Share
$-8,66
Pertumbuhan Pendapatan 3T
+16,8%
52W High
$46,50
52W Low
$25,81
$25,81
Rentang 52 Minggu
$46,50
Як RARE виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка RARE vs аналоги Biotechnology
P/E
—
▼
0%
di bawah
rekan
(18,8)
vs Rekan
vs Industri
Undervalued
P/S
3,5
▼
73%
di bawah
rekan
(12,9)
vs Rekan
vs Industri
Undervalued
P/B
15,2
▲
519%
di atas
rekan
(2,5)
vs Rekan
vs Industri
Overvalued
Дивідендна дохідність
—
▼
0%
di bawah
rekan
(0,0%)
vs Rekan
vs Industri
Yield rendah
Прибутковість RARE vs аналоги Biotechnology
ROE
-414,2%
▼
515%
di bawah
rekan
(-67,3%)
vs Rekan
vs Industri
Lemah
Net margin
-92,0%
▲
68%
di atas
rekan
(-286,8%)
vs Rekan
vs Industri
Di bawah rata-rata
Валова маржа
84,7%
▲
8%
di atas
rekan
(78,6%)
vs Rekan
vs Industri
Lemah
ROA
-43,7%
▲
7%
di atas
rekan
(-46,7%)
vs Rekan
vs Industri
Sejajar
Фінансове здоровʼя RARE vs аналоги Biotechnology
D/E ratio
8352,1
▼
0%
di bawah
rekan
(0,0)
vs Rekan
vs Industri
Utang tinggi
Поточна ліквідність
1,9
▼
57%
di bawah
rekan
(4,4)
vs Rekan
vs Industri
Likuiditas rendah
Beta
0,1
▼
89%
di bawah
rekan
(1,0)
vs Rekan
vs Industri
Lebih volatil
Радар фундаменталів RARE
RARE
Median rekan
Industri
RARE прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
RARE vs аналоги: ключові метрики
Berita Terbaru
Xanadu: Debut Publik Langka Perusahaan Kuantum Fotonik Full-Stack pada 27 Maret – …
Yahoo Finance · Mar 25
USA Rare Earth (USAR) Turun 8.82% setelah Legislator Mempertanyakan Konflik Kepentingan Lutnick
Yahoo Finance · Mar 22
USA Rare Earth vs. MP Materials: Saham Tambang Manakah yang Harus Anda …
Yahoo Finance · Mar 21
How CNBC Cures is bringing rare disease stories to a national audience
CNBC · Mar 21
Tiga Perusahaan Membangun Kembali Senjata Langka-Bumi Amerika
Yahoo Finance · Mar 21